HUT69725A - Process for producing compositions for preventing allograft rejection - Google Patents

Process for producing compositions for preventing allograft rejection Download PDF

Info

Publication number
HUT69725A
HUT69725A HU9400930A HU9400930A HUT69725A HU T69725 A HUT69725 A HU T69725A HU 9400930 A HU9400930 A HU 9400930A HU 9400930 A HU9400930 A HU 9400930A HU T69725 A HUT69725 A HU T69725A
Authority
HU
Hungary
Prior art keywords
receptor
ligand
antibody
lfa
inhibitor
Prior art date
Application number
HU9400930A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9400930D0 (en
Inventor
Mitsuaki Isobe
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HU9400930D0 publication Critical patent/HU9400930D0/hu
Publication of HUT69725A publication Critical patent/HUT69725A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU9400930A 1991-10-01 1992-09-29 Process for producing compositions for preventing allograft rejection HUT69725A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01

Publications (2)

Publication Number Publication Date
HU9400930D0 HU9400930D0 (en) 1994-06-28
HUT69725A true HUT69725A (en) 1995-09-28

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9400930A HUT69725A (en) 1991-10-01 1992-09-29 Process for producing compositions for preventing allograft rejection

Country Status (8)

Country Link
EP (1) EP0610298A1 (es)
JP (1) JPH07502727A (es)
AU (1) AU667487B2 (es)
CA (1) CA2120500A1 (es)
HU (1) HUT69725A (es)
MX (1) MX9205637A (es)
WO (1) WO1993006864A1 (es)
ZA (1) ZA927503B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
EP0606518B1 (en) * 1988-09-28 2003-07-30 Dana Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
EP0387701B1 (en) * 1989-03-09 1992-08-12 Boehringer Ingelheim Pharmaceuticals Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1990013316A1 (en) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination of hiv-1 infected cells
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method

Also Published As

Publication number Publication date
JPH07502727A (ja) 1995-03-23
CA2120500A1 (en) 1993-04-15
AU2782992A (en) 1993-05-03
AU667487B2 (en) 1996-03-28
ZA927503B (en) 1993-05-03
HU9400930D0 (en) 1994-06-28
WO1993006864A1 (en) 1993-04-15
EP0610298A1 (en) 1994-08-17
MX9205637A (es) 1993-05-01

Similar Documents

Publication Publication Date Title
JP4751493B2 (ja) Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
EP0656789B1 (en) Method for treating a lfa-1-mediated disorder
DE69916807T2 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US7638121B2 (en) Methods for human allografting
BENHAIM et al. A long-term study of allogeneic rat hindlimb transplants immunosuppressed with RS-61443
US20070244053A1 (en) Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
Perico et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation.
Irintchev et al. Cellular and molecular reactions in mouse muscles after myoblast implantation
HUT69725A (en) Process for producing compositions for preventing allograft rejection
JPH11500742A (ja) 免疫抑制剤としてのヒアルロン酸の使用
WO1994016728A1 (fr) Anticorps monoclonaux anti-lfa-1 pour la preparation d'un medicament destine a prevenir le rejet des greffes d'organes
CA2486759C (en) Universal chimera bank
Maeda et al. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming.
Autenried et al. Cyclosporine blocks the induction of class I and class II MHC products in mouse kidney by graft-vs-host disease.
DE69737888T2 (de) Anti-mhc klasse ii bindungsreagentien zur verwendung bei xenotransplantationen
CA2460042C (en) Inhibition of antigen presentation with poorly catabolized polymers
Heineman Modification of graft survival by transfusion of the donor: a study in rats
JP2001172188A (ja) 免疫寛容誘導剤
Sun et al. Transplant vascular sclerosis: from pathogenesis to prevention
Immunomodulation Proposed Mechanisms of
Casey Mechanisms Responsible for Indefinite Survival of Cardiac Allografts Induced by R73 Monoclonal Antibody in a Rat Model
Granger et al. Section IV-Transplantation and Immunology

Legal Events

Date Code Title Description
DFA9 Temporary prot. cancelled due to abandonment